<DOC>
	<DOCNO>NCT01948193</DOCNO>
	<brief_summary>The purpose study describe immunogenicity safety novel DTaP- IPV- Hep B-PRT~T fully liquid combine hexavalent vaccine ( Hexaxim™ ) administer 6 , 10 14 week age infant born mother document serum anti-hepatitis B surface antigen ( HBsAg ) serology negative India . Primary Objective : - To evaluate immunogenicity study vaccine term seroprotection [ diphtheria toxoid , tetanus toxoid , poliovirus type 1 , 2 3 , Haemophilus influenzae type b ( Hib ) polysaccharide ( PRP ) , hepatitis B ( Hep B ) ] vaccine response pertussis antigens [ pertussis toxoid ( PT ) filamentous haemagglutinin ( FHA ) ] one month third dose . Secondary Objectives : - To describe immunogenicity study vaccine , first dose one month third dose . - To describe safety dos study vaccine .</brief_summary>
	<brief_title>Study DTaP-IPV-Hep B-PRP~T Combined Vaccine Indian Infants Previously Given Dose Hepatitis B Vaccine Birth</brief_title>
	<detailed_description>All participant receive total 4 dos Hep B , i.e . one dose Hep B monovalent vaccine give birth follow 3 dos Sanofi Pasteur 's hexavalent vaccine give 6 , 10 14 week age context study . Participants parent attend four clinic visit ; expect participation study approximately 3 month .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 4256 day ( 6 8 week ) day inclusion Born full term pregnancy ( ≥37 week ) birth weight ≥2.5 kg Informed consent form sign parent ( ) legally acceptable representative Subject parent/legally acceptable representative able attend schedule visit comply trial procedure Born know hepatitis B surface antigen ( HBsAg ) seronegative mother ( document laboratory result HBsAg assay maternal blood sample perform last trim pregnancy available ) Have receive one document dose Hep B vaccine oral poliovirus vaccine ( OPV ) birth per national recommendation . Participation another clinical trial 4 week precede trial inclusion plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede first trial vaccination ( except Bacillus CalmetteGuerin [ BCG ] vaccine ) plan receipt vaccine within period 8 day 8 day subsequent trial vaccination Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis ( expect birth dose OPV per national recommendation ) hepatitis B ( except birth dose Hep B vaccine ) diseases Hib infection trial vaccine another vaccine Past current receipt immune globulin , blood bloodderived product plan administration trial Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy since birth ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week since birth ) History diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B , Hib infection ( confirm either clinically , serologically microbiologically ) Known personal maternal history Human Immunodeficiency Virus ( HIV ) hepatitis C seropositivity Known systemic hypersensitivity vaccine component , history lifethreatening reaction trial vaccine vaccine contain substance Known thrombocytopenia , report parent/legally acceptable representative Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination In emergency setting , hospitalize involuntarily Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( axillary temperature ≥38°C ) day inclusion ( prospective subject include study condition resolve febrile event subside ) Identified natural adopt child Investigator , relatives employee direct involvement propose study History seizure .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Whooping Cough</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>DTaP IPV-Hep B-PRP~T combined vaccine ( Hexaxim™ )</keyword>
</DOC>